Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Precipio Q2 2026 Revenue Hits $7.0M, Cash Improves

Aug 14, 2026, 4:06 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The company posted solid Q2 revenue growth and a positive Adjusted EBITDA, with a robust cash position that reduces liquidity risk. A positive interpretation of the Aug 17 call could lift sentiment and provide a near-term price catalyst, especially given the first-time revenue milestone and non-dilutive cash generation.

AI summary

What happened, with direct paths to the underlying reporting

Precipio reported Q2 2026 revenue of $7.0M, marking 22% YoY growth and first-time revenue above $7M. Pathology revenue was $6.1M and product revenue $0.9M, with Adjusted EBITDA of $0.4M as momentum strengthens. Operating cash flow was $0.7M, leaving over $3M in cash, supporting improved liquidity ahead of the Aug 17 shareholder call.

Q2 revenue $7.0M. YoY +22% from $5.7M.
Pathology revenue $6.1M. Product revenue $0.9M.
Adjusted EBITDA $0.4M. Improvement from Q1-2026 $(0.2)M.
Cash flow from operations $0.7M. End cash balance >$3M.
Investor call Aug 17, 2026 at 5 PM ET.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.